Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | ADK | P55263 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17303458 | 0.85 | KDM4E (0.77) | KDM4EALDH1A1NISCHPARP1PDE4A | |
| SCHEMBL1060312 | 0.84 | KDM4E (1.00) | KDM4EALDH1A1NISCHPARP1PDE4A | |
| Hydrochloric Acid SCHEMBL3895818 | 0.82 | KDM4E (0.96) | KDM4EALDH1A1NISCHPARP1PDE4A | |
| SCHEMBL5941063 | 0.82 | KDM4E (0.72) | KDM4EALDH1A1NISCHPARP1PDE4A | |
| SCHEMBL4619675 | 0.82 | KDM4E (0.62) | KDM4EALDH1A1NISCHPARP1PDE4A | |
| SCHEMBL7383120 | 0.82 | KDM4E (0.72) | KDM4EALDH1A1NISCHPARP1PDE4A | |
| SCHEMBL27972616 | 0.82 | KDM4E (0.96) | KDM4EALDH1A1NISCHPARP1PDE4A | |
| SCHEMBL5481767 | 0.81 | PRKCI (0.55) | KDM4EALDH1A1NISCHPARP1MTOR | |
| SCHEMBL7024684 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1NISCHPARP1PDE4A | |
| SCHEMBL28604462 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1NISCHPARP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115844889-A | Application of hydroxychloroquine and SB431542 in preparation of medicine for treating lupus nephritis | 吉林大学 | 2023-03-28 | — | — | CN | claimed |
| CN-114191434-A | Application of SB431542 in treating and inhibiting lupus nephritis | 吉林大学 | 2022-03-18 | — | — | CN | claimed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | claimed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | claimed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-115844889-A | Application of hydroxychloroquine and SB431542 in preparation of medicine for treating lupus nephritis | 吉林大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-115583946-A | Heterocyclic compounds and their use as CDK inhibitors | 赛诺哈勃药业（成都）有限公司 | 2023-01-10 | — | — | CN | disclosed |
| CN-114191434-A | Application of SB431542 in treating and inhibiting lupus nephritis | 吉林大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-114191434-A | Application of SB431542 in treating and inhibiting lupus nephritis | 吉林大学 | 2022-03-18 | — | — | CN | disclosed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| CN-107793455-A | A kind of ring iridium (III) metal complex and its preparation method and application | 广东医科大学 | 2018-03-13 | — | — | CN | disclosed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | disclosed |
| EP-1893214-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1893598-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135629-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135721-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| EP-1451158-A1 | THERAPEUTIC QUINOLINE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037872-A1 | THERAPEUTIC QUINOLINE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| CN-1243505-A | Benzamidine derivatives | AJINOMOTO KK (JP) | 2000-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | KDM4E 2083/4885ALDH1A1 2630/4885NISCH 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.